Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | MMP2 | P08253 | 3/20 | 0.51 |
| ▸ | MMP9 | P14780 | 2/20 | 0.51 |
| ▸ | MMP13 | P45452 | 2/20 | 0.51 |
| ▸ | MMP1 | P03956 | 1/20 | 0.51 |
| ▸ | MMP3 | P08254 | 1/20 | 0.51 |
| ▸ | MMP12 | P39900 | 1/20 | 0.51 |
| ▸ | MMP14 | P50281 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL811899 | 1.00 | ALDH1A1 (0.55) | ALDH1A1MMP2MMP9MMP13MMP1 | |
| SCHEMBL34118 | 0.96 | ALDH1A1 (0.58) | ALDH1A1MMP2MMP9MMP13MMP1 | |
| SCHEMBL2637714 | 0.96 | ALDH1A1 (0.58) | ALDH1A1MMP2MMP9MMP13MMP1 | |
| Ethylene Glycol SCHEMBL8592846 | 0.94 | ALDH1A1 (0.56) | ALDH1A1MMP2MMP9MMP13MMP1 | |
| SCHEMBL822501 | 0.93 | ALDH1A1 (0.51) | ALDH1A1MMP2MMP9MMP13MMP1 | |
| SCHEMBL15890449 | 0.91 | ALDH1A1 (0.53) | ALDH1A1MMP2MMP9MMP13MMP1 | |
| SCHEMBL14227008 | 0.89 | GAA (0.58) | ALDH1A1MMP2MMP9MMP13MMP1 | |
| SCHEMBL16711543 | 0.89 | ALDH1A1 (0.51) | ALDH1A1MMP2MMP9MMP13MMP1 | |
| SCHEMBL811796 | 0.87 | CA2 (0.54) | ALDH1A1MMP2MMP9MMP13MMP1 | |
| SCHEMBL811362 | 0.87 | CA2 (0.54) | ALDH1A1MMP2MMP9MMP13MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47556-E1 | Optical element compound, optical material, and optical element | CANON KABUSHIKI KAISHA (JP) | 2019-08-06 | — | — | US | disclosed |
| EP-2390684-B1 | OPTICAL ELEMENT COMPOUND, OPTICAL MATERIAL, AND OPTICAL ELEMENT | CANON KK (JP) | 2019-04-24 | — | — | EP | disclosed |
| US-RE47000-E1 | Optical element compound, optical material, and optical element | CANON KABUSHIKI KAISHA (JP) | 2018-08-21 | — | — | US | disclosed |
| US-8829230-B2 | Optical element compound, optical material, and optical element | CANON KABUSHIKI KAISHA (JP) | 2014-09-09 | — | — | US | disclosed |
| US-20140031582-A1 | OPTICAL ELEMENT COMPOUND, OPTICAL MATERIAL, AND OPTICAL ELEMENT | CANON KABUSHIKI KAISHA (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8569541-B2 | Optical element compound, optical material, and optical element | CANON KABUSHIKI KAISHA (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-2390684-A2 | Optical element compound, optical material, and optical element | Canon Kabushiki Kaisha (JP) | 2011-11-30 | — | — | EP | disclosed |
| US-20110288330-A1 | OPTICAL ELEMENT COMPOUND, OPTICAL MATERIAL, AND OPTICAL ELEMENT | CANON KABUSHIKI KAISHA (JP) | 2011-11-24 | — | — | US | disclosed |
| US-20110257146-A1 | Method of Treating Kcnq Related Disorders Using Organozinc Compounds | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257146-A1 | Method of Treating Kcnq Related Disorders Using Organozinc Compounds | KCNQ3, KCNQ1, KCNQ5 | ALDH1A1 2097/4885MMP2 4213/4885MMP9 3557/4885 |
| US-20110288330-A1 | OPTICAL ELEMENT COMPOUND, OPTICAL MATERIAL, AND OPTICAL ELEMENT | CENPE, AXIN2, CCNE2 | ALDH1A1 1823/4885MMP2 4170/4885MMP9 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.